Entacapone and prostate cancer risk in patients with Parkinson's disease.
Identifieur interne : 000283 ( PubMed/Corpus ); précédent : 000282; suivant : 000284Entacapone and prostate cancer risk in patients with Parkinson's disease.
Auteurs : Pasi Korhonen ; Mikko Kuoppam Ki ; Tuire Prami ; Fabian Hoti ; Solomon Christopher ; Juha Ellmén ; Valtteri Aho ; Mikko Vahteristo ; Eero Pukkala ; Jari HaukkaSource :
- Movement disorders : official journal of the Movement Disorder Society [ 1531-8257 ] ; 2015.
Abstract
The association between Parkinson's disease (PD) and prostate cancer, both common in elderly men, is disputable. In the STRIDE-PD study, prostate cancer developed in 9 patients (3.7%) receiving levodopa/carbidopa with entacapone, a catechol-O-methyltransferase inhibitor, versus 2 cases (0.9%) without entacapone. The current pharmacoepidemiological study aimed to determine whether entacapone increases prostate cancer incidence or mortality in PD patients and whether cumulative exposure affects these rates.
DOI: 10.1002/mds.26140
PubMed: 25639262
Links to Exploration step
pubmed:25639262Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Entacapone and prostate cancer risk in patients with Parkinson's disease.</title><author><name sortKey="Korhonen, Pasi" sort="Korhonen, Pasi" uniqKey="Korhonen P" first="Pasi" last="Korhonen">Pasi Korhonen</name><affiliation><nlm:affiliation>EPID Research Oy, Espoo, Finland.</nlm:affiliation></affiliation></author><author><name sortKey="Kuoppam Ki, Mikko" sort="Kuoppam Ki, Mikko" uniqKey="Kuoppam Ki M" first="Mikko" last="Kuoppam Ki">Mikko Kuoppam Ki</name></author><author><name sortKey="Prami, Tuire" sort="Prami, Tuire" uniqKey="Prami T" first="Tuire" last="Prami">Tuire Prami</name></author><author><name sortKey="Hoti, Fabian" sort="Hoti, Fabian" uniqKey="Hoti F" first="Fabian" last="Hoti">Fabian Hoti</name></author><author><name sortKey="Christopher, Solomon" sort="Christopher, Solomon" uniqKey="Christopher S" first="Solomon" last="Christopher">Solomon Christopher</name></author><author><name sortKey="Ellmen, Juha" sort="Ellmen, Juha" uniqKey="Ellmen J" first="Juha" last="Ellmén">Juha Ellmén</name></author><author><name sortKey="Aho, Valtteri" sort="Aho, Valtteri" uniqKey="Aho V" first="Valtteri" last="Aho">Valtteri Aho</name></author><author><name sortKey="Vahteristo, Mikko" sort="Vahteristo, Mikko" uniqKey="Vahteristo M" first="Mikko" last="Vahteristo">Mikko Vahteristo</name></author><author><name sortKey="Pukkala, Eero" sort="Pukkala, Eero" uniqKey="Pukkala E" first="Eero" last="Pukkala">Eero Pukkala</name></author><author><name sortKey="Haukka, Jari" sort="Haukka, Jari" uniqKey="Haukka J" first="Jari" last="Haukka">Jari Haukka</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2015">2015</date><idno type="RBID">pubmed:25639262</idno><idno type="pmid">25639262</idno><idno type="doi">10.1002/mds.26140</idno><idno type="wicri:Area/PubMed/Corpus">000283</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Entacapone and prostate cancer risk in patients with Parkinson's disease.</title><author><name sortKey="Korhonen, Pasi" sort="Korhonen, Pasi" uniqKey="Korhonen P" first="Pasi" last="Korhonen">Pasi Korhonen</name><affiliation><nlm:affiliation>EPID Research Oy, Espoo, Finland.</nlm:affiliation></affiliation></author><author><name sortKey="Kuoppam Ki, Mikko" sort="Kuoppam Ki, Mikko" uniqKey="Kuoppam Ki M" first="Mikko" last="Kuoppam Ki">Mikko Kuoppam Ki</name></author><author><name sortKey="Prami, Tuire" sort="Prami, Tuire" uniqKey="Prami T" first="Tuire" last="Prami">Tuire Prami</name></author><author><name sortKey="Hoti, Fabian" sort="Hoti, Fabian" uniqKey="Hoti F" first="Fabian" last="Hoti">Fabian Hoti</name></author><author><name sortKey="Christopher, Solomon" sort="Christopher, Solomon" uniqKey="Christopher S" first="Solomon" last="Christopher">Solomon Christopher</name></author><author><name sortKey="Ellmen, Juha" sort="Ellmen, Juha" uniqKey="Ellmen J" first="Juha" last="Ellmén">Juha Ellmén</name></author><author><name sortKey="Aho, Valtteri" sort="Aho, Valtteri" uniqKey="Aho V" first="Valtteri" last="Aho">Valtteri Aho</name></author><author><name sortKey="Vahteristo, Mikko" sort="Vahteristo, Mikko" uniqKey="Vahteristo M" first="Mikko" last="Vahteristo">Mikko Vahteristo</name></author><author><name sortKey="Pukkala, Eero" sort="Pukkala, Eero" uniqKey="Pukkala E" first="Eero" last="Pukkala">Eero Pukkala</name></author><author><name sortKey="Haukka, Jari" sort="Haukka, Jari" uniqKey="Haukka J" first="Jari" last="Haukka">Jari Haukka</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="eISSN">1531-8257</idno><imprint><date when="2015" type="published">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The association between Parkinson's disease (PD) and prostate cancer, both common in elderly men, is disputable. In the STRIDE-PD study, prostate cancer developed in 9 patients (3.7%) receiving levodopa/carbidopa with entacapone, a catechol-O-methyltransferase inhibitor, versus 2 cases (0.9%) without entacapone. The current pharmacoepidemiological study aimed to determine whether entacapone increases prostate cancer incidence or mortality in PD patients and whether cumulative exposure affects these rates.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="In-Process"><PMID Version="1">25639262</PMID><DateCreated><Year>2015</Year><Month>04</Month><Day>13</Day></DateCreated><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1531-8257</ISSN><JournalIssue CitedMedium="Internet"><Volume>30</Volume><Issue>5</Issue><PubDate><Year>2015</Year><Month>Apr</Month><Day>15</Day></PubDate></JournalIssue><Title>Movement disorders : official journal of the Movement Disorder Society</Title><ISOAbbreviation>Mov. Disord.</ISOAbbreviation></Journal><ArticleTitle>Entacapone and prostate cancer risk in patients with Parkinson's disease.</ArticleTitle><Pagination><MedlinePgn>724-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/mds.26140</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The association between Parkinson's disease (PD) and prostate cancer, both common in elderly men, is disputable. In the STRIDE-PD study, prostate cancer developed in 9 patients (3.7%) receiving levodopa/carbidopa with entacapone, a catechol-O-methyltransferase inhibitor, versus 2 cases (0.9%) without entacapone. The current pharmacoepidemiological study aimed to determine whether entacapone increases prostate cancer incidence or mortality in PD patients and whether cumulative exposure affects these rates.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We performed a retrospective cohort study using population-wide health care registers with patient-level linkage. Prostate cancer incidence and mortality were modeled by Cox's proportional hazards models.</AbstractText><AbstractText Label="RESULTS AND CONCLUSIONS" NlmCategory="CONCLUSIONS">Use of entacapone with l-dopa/dopa decarboxylase inhibitor caused no increased risk of prostate cancer incidence (hazard ratio [HR]: 1.05; 95% confidence interval: 0.76-1.44) or mortality (0.93; 0.43-1.98). The HR for cumulative entacapone use of >360 days versus never-use was 0.82 (0.56-1.18) for prostate cancer incidence and 1.27 (0.60-2.72) for prostate cancer mortality.</AbstractText><CopyrightInformation>© 2015 International Parkinson and Movement Disorder Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Korhonen</LastName><ForeName>Pasi</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>EPID Research Oy, Espoo, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kuoppamäki</LastName><ForeName>Mikko</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Prami</LastName><ForeName>Tuire</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Hoti</LastName><ForeName>Fabian</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Christopher</LastName><ForeName>Solomon</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Ellmén</LastName><ForeName>Juha</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Aho</LastName><ForeName>Valtteri</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Vahteristo</LastName><ForeName>Mikko</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Pukkala</LastName><ForeName>Eero</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Haukka</LastName><ForeName>Jari</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>01</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mov Disord</MedlineTA><NlmUniqueID>8610688</NlmUniqueID><ISSNLinking>0885-3185</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">entacapone</Keyword><Keyword MajorTopicYN="N">levodopa</Keyword><Keyword MajorTopicYN="N">pharmacoepidemiology</Keyword><Keyword MajorTopicYN="N">prostate cancer</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>4</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2014</Year><Month>11</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>11</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="aheadofprint"><Year>2015</Year><Month>1</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>2</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>2</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>2</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25639262</ArticleId><ArticleId IdType="doi">10.1002/mds.26140</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000283 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000283 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:25639262
|texte= Entacapone and prostate cancer risk in patients with Parkinson's disease.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:25639262" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |